FDA Approves New Treatment for Thyroid Eye Disease - Quiz - MDSpire

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Original Source(s)

FDA Approves New Treatment for Thyroid Eye Disease

  • by Kathryn Wighton

  • June 29, 2026

Related Content

HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

AI Tool May Cut Macular Edema Referrals

An artificial intelligence–based optical coherence tomography pathway met noninferiority criteria for false-positive diabetic macular edema referrals and was associated with fewer referral decisions in a randomized clinical trial.

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.